Developer docs
API playgroundTry for free, no card

Search company profiles

SyntaxBio

Full company profile

uuid00078xu

Namestring
SyntaxBio
Legal namestring
Syntax Bio
Websiteurl
syntax-bio.com
Company typeenum
Private
Founded yearint
2024
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell differentiation platform, CRISPR gene activation, stem cell programming, cell therapy discovery, biopharma R&D partnerships
Industry3 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy Discovery Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Biopharma Discovery Partnerships
TypeLicensing Royalties
Description

Upfront R&D payments, milestone-based fees, and royalties from biopharmaceutical companies. Capital-efficient model that captures significant downstream economics from therapeutic development programs.

syntax-bio.com
2Platform Collaboration Fees
TypeProfessional Services
Description

Partnerships structured with upfront payments for platform access and evaluation, with additional payments tied to development milestones.

syntax-bio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Cellgalgorithm
Description

Proprietary CRISPR-based platform technology for controlling gene activity in human stem cells to program step-wise cellular differentiation processes

syntax-bio.com
+1 more record
Core offering1 text field

Syntax Bio develops a proprietary CRISPR-based Cellgorithm™ discovery platform that programs step-wise cellular differentiation processes by providing customizable, epigenetic instructions that mimic human embryonic development. The platform enables rapid generation of a wide diversity of functional cell types from human stem cells with reduced growth factor requirements, and is delivered through biopharma discovery partnerships including upfront R&D payments, milestone fees, and royalties. The company's lead therapeutic program uses this platform to produce insulin-producing pancreatic beta cells for Type 1 Diabetes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Differentiation timeline reduced from 4 months to less than 2 weeks
+1 more record
Product overview1 text field

SyntaxBio operates as a preclinical-stage synthetic biology company offering the Cellgalgorithm Platform as its core technology, complemented by the proGuide programmable gene activation system. The platform provides customizable, epigenetic instructions to program step-wise cellular differentiation processes, enabling faster production of various cell types from human stem cells. The company's primary therapeutic focus is the Pancreatic Beta Cell Therapy Program for Type 1 Diabetes. Business model includes biopharma discovery partnerships structured with upfront R&D payments, milestone-based fees, and royalties. Collaborations with Ajinomoto evaluate StemFit culture media products for platform compatibility.

Product and service3 records
1Cellgorithm™ Platform
CategoryCell Differentiation Discovery Platform
Description

CRISPR-based discovery platform providing customizable, epigenetic instructions to program step-wise cellular differentiation processes, mimicking human development to generate functional cell types with reduced growth factor requirements. Sold to large biopharmaceutical organizations and academic medical centers through discovery partnerships.

2proGuide System
CategoryGene Activation Technology System
Description

Programmable gene activation system using CRISPR-based technology to control gene expression with temporal precision, enabling ordered activation of genes to address challenges in cellular developmental programming.

3Pancreatic Beta Cell Therapy Program
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-23
Description

Strategic collaboration announced June 23, 2026 to advance stem cell innovation. Details focused on combining Applied StemCell's expertise with Syntax Bio's Cellgalgorithm platform.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-22
Description

Collaboration to evaluate Ajinomoto Group's StemFit™ stem cell culture products using Syntax Bio's Cellgorithm™ platform. AHN provides StemFit™ culture media products to demonstrate platform compatibility and workflow optimization for next-generation cell therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

R&D collaboration to advance stem cell-derived pancreatic beta cell therapies for type 1 diabetes. Mayo Clinic also participated as an investor in the expanded Series A round. Collaboration aims to advance therapeutic development through preclinical proof of concept.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

bit.bio operates a cell programming platform (opti-ox) that genetically engineers iPSCs into specific cell types — the closest direct competitor to Syntax Bio's Cellgorithm, serving similar biopharma discovery customers with comparable differentiation technology.

TypeDirect peer
Description

BlueRock Therapeutics (a Bayer-owned subsidiary) develops engineered cell therapies using iPSC-derived pluripotent cells, with a similar focus on differentiation protocols for regenerative medicine applications including cell therapy for diseases like Parkinson's.

TypeBroad incumbent
Description

Sana Biotechnology develops engineered cells as medicines, including iPSC-derived allogeneic cell therapies, positioning it as a broad incumbent with overlapping programmable cell therapy capabilities targeting similar indications.

4Notch Therapeutics
TypeDirect peer
Description

Notch Therapeutics develops iPSC-derived immune cell therapies using proprietary Engineered Thymic Niche technology for T-cell manufacturing, operating as a direct peer in the programmable cell therapy manufacturing space.

TypeBroad incumbent
Description

Ginkgo Bioworks operates a broad synthetic biology platform that includes cell engineering services, positioned as a broad incumbent that offers programmable biology capabilities overlapping with Syntax Bio's CRISPR-based differentiation approach.

TypeDirect peer
Description

Century Therapeutics develops engineered iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases, positioning it as a direct peer in the iPSC-based cell therapy development space that Syntax Bio's platform enables.

TypeDirect peer
Description

Fate Therapeutics is a clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell products, directly competing for the same regenerative medicine / cell therapy customer base that Syntax Bio serves with its differentiation platform.

8Aspect Biosystems
TypeDirect peer
Description

Aspect Biosystems develops bioprinted tissue therapeutics using proprietary cell differentiation and 3D bioprinting technology, representing a direct peer in cell differentiation platforms for therapeutic development.

TypeEmerging player
Description

Cellino Biotech combines AI, laser editing, and stem cell biology for autologous cell therapy manufacturing, representing an emerging peer addressing scalability and reproducibility in cell therapy manufacturing.

10TreeFrog Therapeutics
TypeEmerging player
Description

TreeFrog Therapeutics offers a cell therapy manufacturing platform (C-Stem) that encapsulates and differentiates stem cells at scale, representing an emerging peer focused on solving manufacturing scalability — a key customer pain point Syntax Bio addresses.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SyntaxBio

Cell Therapy Discovery Platformsyntax-bio.com

SyntaxBio firmographics

Firmographics
Name
SyntaxBio
Legal name
Syntax Bio
Website
https://syntax-bio.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

SyntaxBio industry classification

Industry
Product category
Cell Therapy Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Cell differentiation platform
  • CRISPR gene activation
  • Stem cell programming
  • Cell therapy discovery
  • Biopharma R&D partnerships

Where SyntaxBio is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

SyntaxBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biopharma Discovery Partnerships: Upfront R&D payments, milestone-based fees, and royalties from biopharmaceutical companies. Capital-efficient model that captures significant downstream economics from therapeutic development programs.
  2. Platform Collaboration Fees: Partnerships structured with upfront payments for platform access and evaluation, with additional payments tied to development milestones.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

SyntaxBio product offering

Product offering

Core offering

Syntax Bio develops a proprietary CRISPR-based Cellgorithm™ discovery platform that programs step-wise cellular differentiation processes by providing customizable, epigenetic instructions that mimic human embryonic development. The platform enables rapid generation of a wide diversity of functional cell types from human stem cells with reduced growth factor requirements, and is delivered through biopharma discovery partnerships including upfront R&D payments, milestone fees, and royalties. The company's lead therapeutic program uses this platform to produce insulin-producing pancreatic beta cells for Type 1 Diabetes.

Product overview

SyntaxBio operates as a preclinical-stage synthetic biology company offering the Cellgalgorithm Platform as its core technology, complemented by the proGuide programmable gene activation system. The platform provides customizable, epigenetic instructions to program step-wise cellular differentiation processes, enabling faster production of various cell types from human stem cells. The company's primary therapeutic focus is the Pancreatic Beta Cell Therapy Program for Type 1 Diabetes. Business model includes biopharma discovery partnerships structured with upfront R&D payments, milestone-based fees, and royalties. Collaborations with Ajinomoto evaluate StemFit culture media products for platform compatibility.

Differentiator

Problem solved

Functional benefit

Brands

  • Cellgalgorithm: Proprietary CRISPR-based platform technology for controlling gene activity in human stem cells to program step-wise cellular differentiation processes
  • proGuide

Products and services

  • Cellgorithm™ Platform CRISPR-based discovery platform providing customizable, epigenetic instructions to program step-wise cellular differentiation processes, mimicking human development to generate functional cell types with reduced growth factor requirements. Sold to large biopharmaceutical organizations and academic medical centers through discovery partnerships.
  • proGuide System Programmable gene activation system using CRISPR-based technology to control gene expression with temporal precision, enabling ordered activation of genes to address challenges in cellular developmental programming.
  • Pancreatic Beta Cell Therapy Program

Quantifiable outcome

  • Differentiation timeline reduced from 4 months to less than 2 weeks
  • +1 more outcomes

Companies that use SyntaxBio

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

SyntaxBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

SyntaxBio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Applied StemCellcoreTechnology or Integration · 23 June 2026Strategic collaboration announced June 23, 2026 to advance stem cell innovation. Details focused on combining Applied StemCell's expertise with Syntax Bio's Cellgalgorithm platform.
  • Ajinomoto Health & Nutrition North America, Inc.coreTechnology or Integration · 22 June 2026Collaboration to evaluate Ajinomoto Group's StemFit™ stem cell culture products using Syntax Bio's Cellgorithm™ platform. AHN provides StemFit™ culture media products to demonstrate platform compatibility and workflow optimization for next-generation cell therapies.
  • Mayo CliniccoreStrategic or Co-development Partner · 9 June 2026R&D collaboration to advance stem cell-derived pancreatic beta cell therapies for type 1 diabetes. Mayo Clinic also participated as an investor in the expanded Series A round. Collaboration aims to advance therapeutic development through preclinical proof of concept.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

SyntaxBio competitors and assessment

Company assessment

Direct peers

  • bit.bio: bit.bio operates a cell programming platform (opti-ox) that genetically engineers iPSCs into specific cell types — the closest direct competitor to Syntax Bio's Cellgorithm, serving similar biopharma discovery customers with comparable differentiation technology.
  • BlueRock Therapeutics: BlueRock Therapeutics (a Bayer-owned subsidiary) develops engineered cell therapies using iPSC-derived pluripotent cells, with a similar focus on differentiation protocols for regenerative medicine applications including cell therapy for diseases like Parkinson's.
  • Notch Therapeutics: Notch Therapeutics develops iPSC-derived immune cell therapies using proprietary Engineered Thymic Niche technology for T-cell manufacturing, operating as a direct peer in the programmable cell therapy manufacturing space.
  • Century Therapeutics: Century Therapeutics develops engineered iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases, positioning it as a direct peer in the iPSC-based cell therapy development space that Syntax Bio's platform enables.
  • Fate Therapeutics: Fate Therapeutics is a clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell products, directly competing for the same regenerative medicine / cell therapy customer base that Syntax Bio serves with its differentiation platform.
  • Aspect Biosystems: Aspect Biosystems develops bioprinted tissue therapeutics using proprietary cell differentiation and 3D bioprinting technology, representing a direct peer in cell differentiation platforms for therapeutic development.

Broad incumbents

  • Sana Biotechnology: Sana Biotechnology develops engineered cells as medicines, including iPSC-derived allogeneic cell therapies, positioning it as a broad incumbent with overlapping programmable cell therapy capabilities targeting similar indications.
  • Ginkgo Bioworks: Ginkgo Bioworks operates a broad synthetic biology platform that includes cell engineering services, positioned as a broad incumbent that offers programmable biology capabilities overlapping with Syntax Bio's CRISPR-based differentiation approach.

Emerging players

  • Cellino Biotech: Cellino Biotech combines AI, laser editing, and stem cell biology for autologous cell therapy manufacturing, representing an emerging peer addressing scalability and reproducibility in cell therapy manufacturing.
  • TreeFrog Therapeutics: TreeFrog Therapeutics offers a cell therapy manufacturing platform (C-Stem) that encapsulates and differentiates stem cells at scale, representing an emerging peer focused on solving manufacturing scalability — a key customer pain point Syntax Bio addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

SyntaxBio social profiles

Digital presence

SyntaxBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SyntaxBio leadership team

Management profile

Number of profiles

Profiles4 records

SyntaxBio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SyntaxBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SyntaxBio

What does SyntaxBio do?

Syntax Bio develops a proprietary CRISPR-based Cellgorithm™ discovery platform that programs step-wise cellular differentiation processes by providing customizable, epigenetic instructions that mimic human embryonic development. The platform enables rapid generation of a wide diversity of functional cell types from human stem cells with reduced growth factor requirements, and is delivered through biopharma discovery partnerships including upfront R&D payments, milestone fees, and royalties. The company's lead therapeutic program uses this platform to produce insulin-producing pancreatic beta cells for Type 1 Diabetes.

Is SyntaxBio a public or private company?

SyntaxBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was SyntaxBio founded?

SyntaxBio was founded in 2024. It employs 11 to 50 people.

Where is SyntaxBio based?

SyntaxBio is headquartered in Chicago, United States, in the North America region.

How does SyntaxBio make money?

Two revenue lines are on record. Biopharma Discovery Partnerships are the primary driver. The others are platform Collaboration Fees.

Who are SyntaxBio's main competitors?

Direct peers on record are bit.bio, BlueRock Therapeutics, Notch Therapeutics, Century Therapeutics, Fate Therapeutics and Aspect Biosystems. Broad incumbents are Sana Biotechnology and Ginkgo Bioworks. Emerging players are Cellino Biotech and TreeFrog Therapeutics.

Does SyntaxBio have an API?

No public API is recorded for SyntaxBio.

What industry is SyntaxBio in?

SyntaxBio's product category is Cell Therapy Discovery Platform. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotech‘The patient need is enormous’: Syntax programs stem cells into pancreatic beta cells in 4 daysSyntax Bio's Cellgorithm platform turns stem cells into pancreatic beta cells in as little as four days, using CRISPR activation to guide gene expression. The company raised $14.4 million in a Series A round to develop a therapy for Type 1 diabetes, with potential applications for Type 2 diabetes.FinancialContent Business PageSyntax Bio Programs Stem Cells Toward Pancreatic Beta Cells in Four DaysSyntax Bio presented data at ISSCR showing its Cellgorithm platform differentiates human iPSCs toward pancreatic beta cells in four days. The company completed screening milestones for its lead program and is now advancing optimization and process development with Breakthrough T1D and Mayo Clinic.Business Wire BlogSyntax Bio to Present New Cellgorithm™ Research at ISSCR iPSC 20th Anniversary Symposium in KyotoSyntax Bio will present Cellgorithm research at the ISSCR iPSC 20th Anniversary Symposium in Kyoto, Oct. 20-22. The research showed human iPSCs differentiated toward pancreatic beta cell states in four days, identifying genetic gridlocks. The findings could enable faster, more reliable production of specialized cells for therapy.AllsciSyntax Bio Raises $14.4M for CRISPR Cell TherapyChicago-based Syntax Bio has closed an expanded Series A funding round totaling $14.4 million, bringing its cumulative funding to over $25 million to advance its CRISPR-based Cellgorithm platform and pancreatic beta cell therapy for type 1 diabetes. The investment was supported by a syndicate of new and existing investors, including Mayo Clinic and Astellas Venture Management, with proceeds earmarked for pre-clinical proof-of-concept development. Concurrently, the company announced leadership transitions, appointing John Craighead as CEO and restructuring its executive team to focus on synthetic biology and AI-driven capabilities.FinSMEsSyntax Bio Expands Series A to $14.4MSyntax Bio, a Chicago-based synthetic biology company, has expanded its Series A funding round to $14.4 million, bringing its total capital raised to over $25 million. The investment was led by Astellas Venture Management and included participation from Illumina Ventures, DCVC Bio, and Mayo Clinic among other investors. Syntax Bio intends to use the funds to expand operations and accelerate development efforts for its CRISPR-based Cellgorithm platform.BioSpaceSyntax Bio Announces Expanded Series A and Leadership AppointmentsSyntax Bio announced an expansion of its Series A funding round to $14.4 million, bringing total capital raised to over $25 million, alongside new leadership appointments to its executive team and board. The company will use the proceeds to advance its proprietary Cellgorithm™ platform and develop a pancreatic beta cell therapy for type 1 diabetes through pre-clinical proof-of-concept. This financing includes participation from new investors such as Draper Associates, Mayo Clinic, and the Illinois Department of Commerce and Economic Opportunity.MorningstarSyntax Bio, Ajinomoto Health & Nutrition North America, Inc. Collaborate to Evaluate Stem Cell Culture Technologies Using Cellgorithm™ PlatformSyntax Bio and Ajinomoto Health & Nutrition North America announced a collaboration to evaluate Ajinomoto's StemFit stem cell culture products using Syntax Bio's Cellgorithm platform. The initiative aims to support regenerative medicine discovery, development, and manufacturing, with data to support Syntax Bio's pipeline. Ajinomoto plans to explore expanding StemFit into advanced cell development and potential manufacturing processes.CRISPR MedicinePress Release Service: Syntax Bio, Ajinomoto Health & Nutrition North America, Inc. Collaborate to Evaluate Stem Cell Culture Technologies Using Cellgorithm™ PlatformSyntax Bio and Ajinomoto Health & Nutrition North America, Inc. have announced a collaboration to evaluate StemFit™ stem cell culture products using Syntax Bio’s Cellgorithm™ platform. The partnership aims to demonstrate compatibility and optimize workflows to support the development of next-generation regenerative medicine therapies.MorningstarSyntax Bio Announces Expanded Series A and Leadership AppointmentsSyntax Bio announced an expanded Series A bringing total funding to over $25 million, with proceeds supporting its Cellgorithm platform and pancreatic beta cell therapy for type 1 diabetes. The company also appointed new executives and board members to strengthen leadership.Crain's Chicago BusinessSyntax Bio teams with Mayo Clinic to find stem cell fix for Type 1 diabetesSyntax Bio has entered into a partnership with the Mayo Clinic to develop stem cell therapies for Type 1 diabetes. The collaboration aims to leverage combined expertise in biotechnology and clinical research to address this chronic condition. This strategic alliance highlights ongoing efforts in regenerative medicine.